Drug Trial Radar · NCT05593094
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Sep 3, 2020
Primary completion
Aug 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in participants with HER2-positive advanced solid tumors with or without brain metastases. The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).
Conditions
- Advanced Solid Tumors
- HER2-positive Breast Cancer
Interventions
ZN-A-1041Drug
ZN-A-1041: escalating doses orally BID at pre-defined dosing regimens to determine the MTD
ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1bDrug
ZN-A-1041: BID via oral administration T-DM1: 3.6 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1bDrug
ZN-A-1041: BID via oral administration T-DXd: 5.4 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1bDrug
ZN-A-1041: BID via oral administration PHESGO dose is 600 mg pertuzumab/600 mg trastuzumab/2000 unites hyaluronidase every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta is 420 mg administered as an intravenous infusion Herceptin is 6 mg/kg administered as an intravenous infusion
ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1cDrug
ZN-A-1041: BID via oral administration T-DM1: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1cDrug
ZN-A-1041: BID via oral administration T-DXd: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1cDrug
ZN-A-1041: BID via oral administration PHESGO: every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta: intravenous infusion Herceptin: intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Incidence of Treatment-emergent Adverse Events of ZN-A-1041 as a Monotherapy in Phase 1aTime frame: 23 days
- The Incidence of Treatment-emergent Adverse Events of ZN-A-1041 in Combination with T-DM1 or with T-DXd, or in Combination with PHESGO or Herceptin plus PerjetaTime frame: 21 days
- RP2DTime frame: Through study completion, an average of 1 year
Locations
36 sites in 7 countries. Site status is shown where the registry gives one.
Arizona Clinical Research Center, Inc.;Hematology Oncology Physicians - Aoa
Tucson, Arizona
TOI Clinical Research
Cerritos, California
UCSF Helen Diller Family CCC
San Francisco, California
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan Hospital
Ann Arbor, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Duke University School of Medicine
Durham, North Carolina
MD Anderson Cancer Center
Houston, Texas
Geelong Hospital
Geelong, Victoria, Australia
Sunshine Hospital
St Albans, Victoria, Australia
Centre Georges Francois Leclerc
Dijon, France
Centre Oscar Lambret
Lille, France
Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes
Lyon, France
Institut Paoli-Calmettes
Marseille, France
Institut de Cancerologie de l Ouest
Saint-Herblain, France
Gustave Roussy
Villejuif, France
EDOG - Institut Claudius Regaud - PPDS
Toulouse, Haute-Garonne, France
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l - PPDS
Parma, Emilia-Romagna, Italy
Asst Papa Giovanni XXIII
Bergamo, Lombardy, Italy
Fondazione Policlinico Universitario A Gemelli-Rome
Magnago, Lombardy, Italy
Auckland City Hospital
Auckland, New Zealand
Instituto Oncologico Dr. Rosell-Hospital Universitari Dexeus-Grupo Quironsalud
Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital Universitario de Jaen
Jaén, Spain
Hospital Beata Maria Ana
Madrid, Spain
Hospital Clinico San Carlos
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Fundacion Instituto Valenciano de Oncologia (IVO)
Valencia, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
Argentona, Barcelona, Spain
Hospital Clinico Universitario de Santiago
Santiago de Compostela, LA Coruna, Spain
Hospital Universitario Ramon y Cajal
A Gudiña, Orense, Spain
Hospital Universitario Virgen del Rocio
Las Cabezas de San Juan, Sevilla, Spain
The Christie
Manchester, Lancashire, United Kingdom
Clatterbridge Cancer Centre
Liverpool, Merseyside, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.